BR112012006252A2 - "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2". - Google Patents
"formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".Info
- Publication number
- BR112012006252A2 BR112012006252A2 BR112012006252A BR112012006252A BR112012006252A2 BR 112012006252 A2 BR112012006252 A2 BR 112012006252A2 BR 112012006252 A BR112012006252 A BR 112012006252A BR 112012006252 A BR112012006252 A BR 112012006252A BR 112012006252 A2 BR112012006252 A2 BR 112012006252A2
- Authority
- BR
- Brazil
- Prior art keywords
- abt
- crystalline forms
- bcl
- solvates
- treatment
- Prior art date
Links
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 title abstract 2
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000012453 solvate Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000002424 anti-apoptotic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24405109P | 2009-09-20 | 2009-09-20 | |
| PCT/US2010/048949 WO2011034934A1 (en) | 2009-09-20 | 2010-09-15 | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012006252A2 true BR112012006252A2 (pt) | 2017-05-23 |
Family
ID=43064468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012006252A BR112012006252A2 (pt) | 2009-09-20 | 2010-09-15 | "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2". |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8362014B2 (enExample) |
| EP (1) | EP2477972A1 (enExample) |
| JP (2) | JP2013505249A (enExample) |
| KR (1) | KR20120085781A (enExample) |
| CN (2) | CN105820138A (enExample) |
| AU (1) | AU2010295717B2 (enExample) |
| BR (1) | BR112012006252A2 (enExample) |
| CA (1) | CA2771984A1 (enExample) |
| IL (1) | IL218403A0 (enExample) |
| MX (1) | MX2012003408A (enExample) |
| NZ (1) | NZ598461A (enExample) |
| RU (1) | RU2551376C2 (enExample) |
| TW (1) | TWI488853B (enExample) |
| WO (1) | WO2011034934A1 (enExample) |
| ZA (1) | ZA201202891B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102209729B (zh) * | 2008-11-07 | 2016-05-25 | 安进研发（慕尼黑）股份有限公司 | 小儿急性淋巴细胞白血病的治疗方法 |
| RS58827B1 (sr) | 2008-11-07 | 2019-07-31 | Amgen Res Munich Gmbh | Tretiranje akutne limfoblastne leukemije |
| US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| US20100280031A1 (en) * | 2009-04-30 | 2010-11-04 | Paul David | Lipid formulation of apoptosis promoter |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| TWI471321B (zh) * | 2009-06-08 | 2015-02-01 | 亞培公司 | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| CN105820138A (zh) | 2009-09-20 | 2016-08-03 | Abbvie 公司 | 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物 |
| JP5779591B2 (ja) * | 2009-12-22 | 2015-09-16 | アッヴィ・インコーポレイテッド | Ａｂｔ−２６３カプセル剤 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| PL2958916T3 (pl) * | 2013-02-21 | 2019-01-31 | Pfizer Inc. | Stałe postacie selektywnego inhibitora CDK4/6 |
| WO2014160071A1 (en) | 2013-03-14 | 2014-10-02 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of glutamine-addicted cancers |
| CA2909380A1 (en) * | 2013-04-21 | 2014-10-30 | Yeda Research And Development Co. Ltd. | Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w |
| EP3099380B1 (en) | 2014-01-28 | 2021-08-11 | Buck Institute for Research on Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| WO2015157120A1 (en) * | 2014-04-06 | 2015-10-15 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| WO2018085069A1 (en) | 2016-11-03 | 2018-05-11 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
| TR201703149A2 (tr) * | 2017-03-01 | 2018-09-21 | Univ Yeditepe | Kemoterapi̇k i̇laç kompozi̇syonu |
| CN108727387B (zh) * | 2018-07-25 | 2021-03-16 | 天津大学 | 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法 |
| CN109053738B (zh) * | 2018-08-29 | 2020-10-16 | 浙江工业大学 | 一种依鲁替尼的溶剂化物及其制备方法 |
| JP7417356B2 (ja) | 2019-01-25 | 2024-01-18 | 株式会社ソニー・インタラクティブエンタテインメント | ロボット制御システム |
| US11285159B2 (en) | 2019-11-05 | 2022-03-29 | Abbvie Inc. | Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2713507A (en) | 1948-10-04 | 1955-07-19 | Garlinghouse Brothers | Concrete bucket |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US7075365B1 (en) | 2004-04-22 | 2006-07-11 | Altera Corporation | Configurable clock network for programmable logic device |
| PT1888550E (pt) * | 2005-05-12 | 2014-09-03 | Abbvie Bahamas Ltd | Promotores de apoptose |
| EP2061560A2 (en) * | 2006-09-05 | 2009-05-27 | Abbott Laboratories | Bcl inhibitors for treating platelet excess |
| JP4202380B2 (ja) * | 2006-10-17 | 2008-12-24 | シャープ株式会社 | 画像形成装置 |
| MX2010006260A (es) | 2007-12-06 | 2010-08-23 | Abbott Lab | Composiciones orales de abt-263 para tratar cancer. |
| CN101220008B (zh) * | 2008-01-21 | 2011-04-27 | 中国科学院广州生物医药与健康研究院 | 化合物abt-263的合成方法 |
| US8168784B2 (en) * | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| US8140876B2 (en) * | 2009-01-16 | 2012-03-20 | International Business Machines Corporation | Reducing power consumption of components based on criticality of running tasks independent of scheduling priority in multitask computer |
| JP2010259520A (ja) | 2009-04-30 | 2010-11-18 | Motoji Ono | 搬送機構、トレッドミル及びコンベア |
| US8362013B2 (en) * | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| US20110047552A1 (en) * | 2009-05-11 | 2011-02-24 | Raytheon Bbn Technologies Corp. | Energy-aware process environment scheduler |
| US8291422B2 (en) * | 2009-05-11 | 2012-10-16 | Bbn Technologies Corp. | Energy-aware computing environment scheduler |
| CN105820138A (zh) | 2009-09-20 | 2016-08-03 | Abbvie 公司 | 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物 |
| CN101798292A (zh) * | 2010-03-29 | 2010-08-11 | 无锡好芳德药业有限公司 | ABT-263衍生的新型Bcl-2蛋白抑制剂的制备 |
-
2010
- 2010-09-15 CN CN201610194338.4A patent/CN105820138A/zh active Pending
- 2010-09-15 EP EP10757361A patent/EP2477972A1/en not_active Withdrawn
- 2010-09-15 BR BR112012006252A patent/BR112012006252A2/pt not_active IP Right Cessation
- 2010-09-15 MX MX2012003408A patent/MX2012003408A/es unknown
- 2010-09-15 CA CA2771984A patent/CA2771984A1/en not_active Abandoned
- 2010-09-15 US US12/882,576 patent/US8362014B2/en active Active
- 2010-09-15 RU RU2012115851/04A patent/RU2551376C2/ru not_active IP Right Cessation
- 2010-09-15 JP JP2012529878A patent/JP2013505249A/ja active Pending
- 2010-09-15 NZ NZ598461A patent/NZ598461A/en not_active IP Right Cessation
- 2010-09-15 CN CN2010800417753A patent/CN102695702A/zh active Pending
- 2010-09-15 WO PCT/US2010/048949 patent/WO2011034934A1/en not_active Ceased
- 2010-09-15 KR KR1020127010148A patent/KR20120085781A/ko not_active Ceased
- 2010-09-15 AU AU2010295717A patent/AU2010295717B2/en not_active Ceased
- 2010-09-20 TW TW099131885A patent/TWI488853B/zh not_active IP Right Cessation
-
2011
- 2011-07-28 US US13/193,013 patent/US8513243B2/en not_active Expired - Fee Related
-
2012
- 2012-02-29 IL IL218403A patent/IL218403A0/en unknown
- 2012-04-19 ZA ZA2012/02891A patent/ZA201202891B/en unknown
-
2015
- 2015-07-17 JP JP2015142670A patent/JP2015232006A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2012115851A (ru) | 2013-10-27 |
| IL218403A0 (en) | 2012-04-30 |
| CA2771984A1 (en) | 2011-03-24 |
| AU2010295717B2 (en) | 2014-09-11 |
| US8362014B2 (en) | 2013-01-29 |
| TWI488853B (zh) | 2015-06-21 |
| ZA201202891B (en) | 2013-09-25 |
| JP2013505249A (ja) | 2013-02-14 |
| CN102695702A (zh) | 2012-09-26 |
| JP2015232006A (ja) | 2015-12-24 |
| AU2010295717A1 (en) | 2012-03-22 |
| NZ598461A (en) | 2013-12-20 |
| TW201116526A (en) | 2011-05-16 |
| US20110071151A1 (en) | 2011-03-24 |
| KR20120085781A (ko) | 2012-08-01 |
| US20110294811A1 (en) | 2011-12-01 |
| EP2477972A1 (en) | 2012-07-25 |
| MX2012003408A (es) | 2012-08-03 |
| WO2011034934A1 (en) | 2011-03-24 |
| US8513243B2 (en) | 2013-08-20 |
| CN105820138A (zh) | 2016-08-03 |
| RU2551376C2 (ru) | 2015-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012006252A2 (pt) | "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2". | |
| UY32598A (es) | Sal de abt-263 y formas en estado sólido de la misma | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| SE0301700D0 (sv) | Novel compounds | |
| BR112015032736A2 (pt) | inibidores de bromodomínio cristalino | |
| BRPI0418251C1 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
| TW200640908A (en) | Chemical compounds | |
| DE60237115D1 (de) | Synergistische Kombination von (-) -Gossypol mit Docetaxel oder Paclitaxel zur Behandlung von Krebs. | |
| CL2008001813A1 (es) | Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04). | |
| SV2002000245A (es) | Oxazolidinonas substituidas y su uso ref. lea 34122-sv | |
| ECSP088329A (es) | Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8 | |
| UA108193C2 (uk) | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| ECSP088561A (es) | Derivados de pirimidinil-aril-urea que son inhibidores de fgf | |
| CL2007003756A1 (es) | Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer. | |
| CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. | |
| BR112013012740A2 (pt) | sais e formas cristalinas de um agente que induz apoptose | |
| EA200970532A1 (ru) | Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола | |
| UY30759A1 (es) | Compuestos quimicos | |
| MX2010004491A (es) | Derivados de piridina y pirazina utiles en el tratamiento de trastornos proliferativos celulares. | |
| EA200900613A1 (ru) | Спирокетоновые ингибиторы ацетил-коа-карбоксилаз | |
| NO20064584L (no) | Tetrahydropyridoindolderivater | |
| BR112015009559A2 (pt) | uso de composto antissenso na preparação de medicamento para tratamento de cãncer, composto antissenso e composição farmacêutica | |
| NZ596047A (en) | Stabilized lipid formulation of apoptosis promoter | |
| BRPI0407662A (pt) | derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas | |
| DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B25B | Requested transfer of rights rejected |
Owner name: ABBOTT LABORATORIES (US) |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |